Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women

被引:64
作者
Cella, David [1 ,2 ]
Land, Stephanie R. [2 ,3 ,4 ]
Chang, Chih-Hung [2 ,5 ]
Day, Richard [2 ,4 ]
Costantino, Joseph P. [2 ,3 ,4 ]
Wolmark, Norman [2 ,6 ]
Ganz, Patricia A. [2 ,7 ,8 ]
机构
[1] Evanston Northwestern Healthcare, Ctr Outcomes Res & Educ, Evanston, IL 60201 USA
[2] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA
[3] NSABP Biostat Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA
[5] Northwestern Univ, Buehler Ctr Aging Hlth & Soc, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[7] Univ Calif Los Angeles, Sch Med & Publ Hlth, Los Angeles, CA USA
[8] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
关键词
breast cancer; breast cancer prevention; symptoms; scale; eight; menopausal; endocrine; NSABP; NHLBI (PEPI); BCPT; P-1;
D O I
10.1007/s10549-007-9682-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate scalability of a symptom scale administered to women enrolled in the Breast Cancer Prevention Trial (BCPT) (P-1) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP).Patients and methods: Responses of 11,064 women recruited into a study of 20 mg daily tamoxifen versus placebo to prevent breast cancer in high-risk women were analyzed. Exploratory factor analyses of the 12 month data were conducted on a random subset of 4,000 women to estimate the factor structure. Baseline data on these same 4,000 women were analyzed to confirm the structure. The remaining sample was divided randomly into two data sets. Data on each set were then grouped by age (35-49, 50-59, or >= 60 years) and treatment (tamoxifen or placebo) to corroborate these analyses. Correlations between the obtained symptom clusters and two standard instruments (SF-36 and CES-D) were examined. Content analysis of open-ended responses was also conducted.Results: Eight clinically-interpretable clusters of symptoms were identified and confirmed: Cognitive symptoms, musculoskeletal pain, vasomotor symptoms, nausea, sexual problems, bladder problems, body image, and vaginal symptoms. Scoring for each scale represented by these eight clusters is provided. Content analysis of open-ended responses suggested four items that are additional candidates: fatigue, back problems, abdominal pain, and leg/foot cramps or pain. Conclusions: Symptoms associated with hormone therapy for breast cancer can vary. Nevertheless, the BCPT Eight Symptom Scale (BESS) can be clustered into clinically relevant and reproducible factors that may be useful in future outcomes research.
引用
收藏
页码:515 / 526
页数:12
相关论文
共 25 条
  • [1] Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors
    Alfano, Catherine M.
    McGregor, Bonnie A.
    Kuniyuki, Alan
    Reeve, Bryce B.
    Bowen, Deborah J.
    Baumgartner, Kathy B.
    Bernstein, Leslie
    Ballard-Barbash, Rachel
    Malone, Kathleen E.
    Ganz, Patricia A.
    McTiernan, Anne
    [J]. PSYCHO-ONCOLOGY, 2006, 15 (11) : 985 - 1000
  • [2] [Anonymous], 1994, SF 36 PHYS MENTAL SU
  • [3] SCREE TEST FOR NUMBER OF FACTORS
    CATTELL, RB
    [J]. MULTIVARIATE BEHAVIORAL RESEARCH, 1966, 1 (02) : 245 - 276
  • [4] Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Day, R
    Ganz, PA
    Costantino, JP
    Cronin, WM
    Wickerham, DL
    Fisher, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2659 - 2669
  • [5] Day R, 2001, ANN NY ACAD SCI, V949, P143
  • [6] Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials
    Fallowfield, L
    Fleissig, A
    Edwards, R
    West, A
    Powles, TJ
    Howell, A
    Cuzick, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) : 1885 - 1892
  • [7] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B
    Costantino, JP
    Wickerham, DL
    Redmond, CK
    Kavanah, M
    Cronin, WM
    Vogel, V
    Robidoux, A
    Dimitrov, N
    Atkins, J
    Daly, M
    Wieand, S
    Tan-Chiu, E
    Ford, L
    Wolmark, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) : 1371 - 1388
  • [8] Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer
    Gallicchio, L
    Lord, G
    Tkaczuk, K
    Danton, M
    Lewis, LM
    Lim, CK
    Flaws, JA
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (01) : 89 - 97
  • [9] BASE-LINE QUALITY-OF-LIFE ASSESSMENT IN THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT BREAST-CANCER PREVENTION TRIAL
    GANZ, PA
    DAY, R
    WARE, JE
    REDMOND, C
    FISHER, B
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (18): : 1372 - 1382
  • [10] Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/progestin interventions trial
    Greendale, GA
    Reboussin, BA
    Hogan, P
    Barnabei, VM
    Shumaker, S
    Johnson, S
    Barrett-Connor, E
    [J]. OBSTETRICS AND GYNECOLOGY, 1998, 92 (06) : 982 - 988